<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638677</url>
  </required_header>
  <id_info>
    <org_study_id>Pacifierstudy20/8/2003</org_study_id>
    <secondary_id>No ISRCTN or NIH grants</secondary_id>
    <nct_id>NCT00638677</nct_id>
  </id_info>
  <brief_title>Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier</brief_title>
  <official_title>Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fennobon oy, Karkkila, Finland (provides the tablets for the pacifier)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Plastone Oy, Konnevesi, Finland (provides the pacifiers)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims:

        1. To develop a food supplement containing a health-promoting probiotic bacteria (B. lactis
           BB12) and xylitol to be administered with a novel soft, possibly occlusion-friendly
           pacifier.

        2. Test in a clinical study how feasible the method is and to study how the intervention
           affects caries occurrence.

      Main hypothesis:

      The administration of B. lactis BB12 and xylitol affects beneficially the dental health of
      the child.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xylitol is known to reduce counts of mutans streptococci (ms) as well as mother-child
      transmission of ms. Possibly xylitol delivered to infants could positively influence
      colonization/metabolism of ms. By combining in a food supplement xylitol and B. lactis BB12
      (a well known probiotic bacteria) we may be able to positively affect both gut and oral
      colonization, reflected in both dental and general health (solid data available on the latter
      aim). Though B. lactis is in wide use in baby formulas and in in vitro tests it apparently is
      safe for the teeth, no clinical studies have looked at effects of its administration to
      infants on oral health. Our study aims to look at caries occurrence in infants who have
      received the xylitol + BB12 food supplement with a pacifier.

      Recruiting of subjects to the study is completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MS colonization</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute infectious diseases</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caries occurrence</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Dental Caries</condition>
  <condition>Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sorbitol tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Xylitol tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xylitol + BB12 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sorbitol</intervention_name>
    <description>Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xylitol</other_name>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylitol + BB12</intervention_name>
    <description>Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Sorbitol</other_name>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <description>Xylitol+BB 12 delivery with a pacifier max until 2 years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sorbitol</other_name>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The infant is healthy

          -  The family agrees to use the novel slow-release pacifier

          -  The infant starts to use the pacifier before the age of 3 months

        Exclusion Criteria:

          -  The child is not healthy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva M SÃ¶derling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assoc. Prof., University of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Care Centre</name>
      <address>
        <city>Muurame and Korpilahti</city>
        <zip>40950</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Eva Soderling</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Oral microbiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorbitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

